ArticleClinical research in cardiology : official journal of the German Cardiac Society2015
Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Preventing atrial fibrillation after cardiac surgery: a single-institution cohort study after implementation of a standardized preventative protocol.Journal of thoracic disease · 2025Article
- The real-world safety profile of ranolazine: pharmacovigilance analysis of the FAERS database.Frontiers in pharmacology · 2025Article
- Unraveling the pharmacological and therapeutic potential of Ranolazine beyond antianginal drug use: a new insight.Experimental biology and medicine (Maywood, N.J.) · 2025Review
- The Role of Ranolazine in the Treatment of Ventricular Tachycardia and Atrial Fibrillation: A Narrative Review of the Clinical Evidence.Biomedicines · 2024Review
- Interventions to prevent postoperative atrial fibrillation in Dutch cardiothoracic centres: a survey study.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2024Article
- Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-Clinical and Clinical Investigations for Possible Repositioning.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Calcium Signaling Silencing in Atrial Fibrillation: Implications for Atrial Sodium Homeostasis.International journal of molecular sciences · 2021Review
- Postoperative Atrial Fibrillation Following Cardiac Surgery: From Pathogenesis to Potential Therapies.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2020Review
- Ranolazine for Prevention of Atrial Fibrillation after Cardiac Surgery: A Systematic Review.Cureus · 2018Review
- Impact of ranolazine on ventricular arrhythmias - A systematic review.Journal of arrhythmia · 2018Review
- Antiarrhythmic Effects of Combining Dofetilide and Ranolazine in a Model of Acutely Induced Atrial Fibrillation in Horses.Journal of cardiovascular pharmacology · 2018Article
- Atrial fibrillation after cardiac surgery: Prevention and management: The Australasian experience.Journal of the Saudi Heart Association · 2018Review
- Ranolazine: safe and effective in a patient with hypertensive cardiomyopathy and multiple episodes of electrical storm.Clinical case reports · 2017Article
- Efficacy of ranolazine in preventing atrial fibrillation following cardiac surgery: Results from a meta-analysis.Journal of arrhythmia · 2017Review
- Monocyte-platelet aggregates and CD11b expression as markers for thrombogenicity in atrial fibrillation.Clinical research in cardiology : official journal of the German Cardiac Society · 2016Article
- Ranolazine: A Contemporary Review.Journal of the American Heart Association · 2016Review
- Ranolazine in Cardiac Arrhythmia.Clinical cardiology · 2016Review
- Ranolazine: Multifaceted Role beyond Coronary Artery Disease, a Recent Perspective.Heart views : the official journal of the Gulf Heart AssociationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostoperative atrial fibrillation (POAF) is a common complication arising after coronary artery bypass grafting (CABG) and valve replacement or repair surgeries. POAF has been associated with increased mortality, morbidity and cost.
methodsThe study was conducted to evaluate the incidence of POAF following CABG, valve or combination surgeries when perioperative ranolazine (1,000 mg preoperatively, then 1,000 mg twice daily for 7 days or until discharge) was or was not added to standard therapy.
resultsA total of 205 patients were evaluated for POAF after CABG, valve or combination surgeries. POAF occurred less frequently in the ranolazine group compared with the non-ranolazine group in unmatched analysis (10.1 vs. 41.9 %, p < 0.0001). After adjusting for potential sources of bias through propensity-score matched-pair analysis and conditional logistic regression, ranolazine was an independent predictor of preventing POAF (p < 0.0001). There were no differences in bradycardia, new renal failure or neurological events between the two groups. Early, symptomatic hypotension occurred more frequently in the ranolazine group (p = 0.0004) although this difference did not persist after 72 h. No significant difference was found in the length of stay in the intensive care unit following cardiac surgery. While a significant difference was found in the hospital readmission rate for a cardiac cause within 30 days in the unmatched analysis (p = 0.046), this difference was nonexistent after matching (p = 0.39). No difference was found in 30-day cardiovascular mortality.
conclusionAdding ranolazine to standard therapy was independently associated with a significant decrease in POAF development after CABG, valve or combination surgeries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.